Quotient (NASDAQ:QTNT) Research Coverage Started at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Quotient (NASDAQ:QTNTGet Rating) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the stock.

Separately, The Goldman Sachs Group dropped their price target on Quotient from $3.00 to $1.50 and set a “neutral” rating on the stock in a research report on Tuesday, April 19th.

Shares of QTNT opened at $0.36 on Tuesday. The business’s 50 day moving average price is $0.50 and its 200-day moving average price is $1.23. Quotient has a 52 week low of $0.27 and a 52 week high of $4.45. The stock has a market cap of $36.94 million, a P/E ratio of -0.27 and a beta of 2.72.

A number of hedge funds have recently added to or reduced their stakes in QTNT. Royal Bank of Canada lifted its position in Quotient by 31.2% in the 2nd quarter. Royal Bank of Canada now owns 23,760 shares of the company’s stock valued at $87,000 after acquiring an additional 5,654 shares in the last quarter. Millennium Management LLC lifted its position in Quotient by 66.3% in the 2nd quarter. Millennium Management LLC now owns 47,878 shares of the company’s stock valued at $174,000 after acquiring an additional 19,089 shares in the last quarter. Invesco Ltd. lifted its position in Quotient by 45.0% in the 2nd quarter. Invesco Ltd. now owns 28,009 shares of the company’s stock valued at $102,000 after acquiring an additional 8,691 shares in the last quarter. Morgan Stanley lifted its position in Quotient by 43.4% in the 2nd quarter. Morgan Stanley now owns 3,489,380 shares of the company’s stock valued at $12,700,000 after acquiring an additional 1,056,803 shares in the last quarter. Finally, Citigroup Inc. lifted its position in Quotient by 114.2% in the 3rd quarter. Citigroup Inc. now owns 10,992 shares of the company’s stock valued at $26,000 after acquiring an additional 5,861 shares in the last quarter. 77.47% of the stock is currently owned by institutional investors and hedge funds.

About Quotient (Get Rating)

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening.

Featured Articles

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.